Developer docs
API playgroundTry for free, no card

Search company profiles

Invetech

Full company profile

uuid0007v3r

Namestring
Invetech
Legal namestring
Invetech Pty. Ltd. and Invetech US LLC
Company typeenum
Private
Founded yearint
1987
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical device manufacturing, cell therapy automation, diagnostic instrument development, contract manufacturing services, IVD product engineering
Industry2 codes
PRIMARYHLAGABAL
Process Development & Tech Transfer Services (CDMO)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Industrial Design Services54142
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Device Contract Manufacturing
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Manufacturing Services
TypeHardware Sales
Description

Manufacturing services for clinical diagnostics instruments, life science instruments, and cell & gene therapy automation platforms. Revenue generated through NPI (New Product Introduction) manufacturing, pilot builds, and commercial-scale production. Operates through ISO 9001, ISO 13485, FDA-registered, ISO Class 7, and GMP manufacturing capabilities.

invetechgroup.com
2Product Development Services
TypeProfessional Services
Description

Design and engineering services from concept through regulatory-ready production. Includes full-service partnership, strategic engineering support, and sustaining engineering services. Revenue generated through project-based engagements.

invetechgroup.com
3Proprietary Platforms and Modules
TypeHardware Sales
Description

Sale of proprietary configurable automation platforms including Korus counterflow centrifuge, Alta formulation and filling systems, Paddle Mixers, and Ensemble modular platforms for diagnostics and CGT applications.

invetechgroup.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Enterprise contract manufacturing - project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is negotiated on a per-project basis based on complexity, volume, and scope of manufacturing or development services required.

invetechgroup.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Korus™
Description

Counterflow Centrifugation System for cell washing and elutriation in cell therapy manufacturing.

invetechgroup.com
+3 more records
Core offering1 text field

Invetech designs, develops and manufactures proprietary automation platforms and provides full-service product development and contract manufacturing for in-vitro diagnostics (IVD) and cell & gene therapy (CGT) companies. The offering spans feasibility, design, engineering, regulatory-ready production and commercial-scale manufacturing, delivered alongside a portfolio of configurable products including the Korus counterflow centrifuge, Alta bag filling system, Paddle Mixer and Ensemble diagnostic platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Defect rate reduction from 50% to <1% for point-of-care device manufacturing over 5 years
+3 more records
Product overview1 text field

Invetech offers a platform-plus-modules architecture combining proprietary configurable automation products with comprehensive development and manufacturing services. The core product portfolio includes the Ensemble modular IVD development platform, Korus counterflow centrifuge system, Paddle Mixer for gentle cell mixing, Alta formulation and fill system, and Single-Use Consumables. These are complemented by service offerings in cell and gene therapy automation, IVD contract manufacturing, and product development services. The company operates manufacturing facilities in San Diego and Melbourne with ISO 13485, ISO 9001 certifications and FDA registration.

Product and service8 records
1Invetech Ensemble
CategoryModular diagnostic platform
Description

Modular diagnostic platform that accelerates product development by combining proven core technologies with customizable configurations for translating assays from lab to benchtop IVD and point-of-care instruments.

2Korus Counterflow Centrifuge System
CategoryCell processing automation
Description

Automated counterflow centrifugation system for cell washing and elutriation in a closed, single-use system, producing cleaner starting material for downstream CGT processing with configurable protocols for different cell types and therapy workflows.

3Paddle Mixer
CategoryCell processing automation
Description

Configurable, low-shear GMP-compatible paddle mixer for cell and gene therapy bioprocessing, designed for gentle mixing of living cells to preserve cell viability with consistent, repeatable agitation across single-use bags.

4Alta Formulation and Fill System
CategoryFill-finish automation
Description

Closed, automated bag filling system for aseptic fill and finish of advanced therapies that accurately dispenses therapeutic product into individual aliquot bags, replacing manual, variable, open processes with a GMP-ready fill operation.

5Single-Use Consumables
CategoryCGT consumables
Description

Purpose-built bags, tubing, fluid path assemblies, and custom components engineered for CGT manufacturing, co-designed with Invetech's automation equipment to deliver closed, aseptic workflows.

6IVD Contract Manufacturing
CategoryContract manufacturing services
Description

ISO-certified contract manufacturing services for clinical diagnostic and life science instruments, from pilot builds to commercial scale, including NPI manufacturing, design-to-manufacture transfer and ongoing production support.

7Cell & Gene Therapy Automation Solutions
CategoryEngineering services for CGT
Description

Custom automation, configurable platforms, and proprietary systems for autologous and allogeneic cell and gene therapies, including end-to-end automation, single-use consumables development, and GMP-aligned manufacturing solutions.

8Product Development Services
CategoryProduct development services
Description

Design and engineering services for diagnostics, medical devices and life sciences covering the full development journey from feasibility through regulatory-ready production, including feasibility, full-service partnership, strategic engineering support and sustaining engineering.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-04
Description

Strategic collaboration announced June 4, 2026, with Invetech serving as General Fluidics' development and scaleup partner for its Axess point-of-care diagnostic platform. Invetech was selected after a global search spanning four continents for its end-to-end manufacturing capability and diagnostics expertise. The partnership aims to accelerate bringing high-quality diagnostic testing from central labs directly to clinics, urgent care centers, and rural settings.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Strategic alliance to advance development and commercialization of Trenchant's fully automated AutoCell Platform for cell and gene therapy manufacturing. Testing data shows the platform could reduce CGT manufacturing costs by up to 80% and manufacturing time by up to 95%. The technology enables point-of-care production from a single unit of whole blood. Early access platform launch planned for early 2027, with full commercial release later that year.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-26
Description

Strategic collaboration to advance cell therapy innovation. Geoffrey Stephens, CEO of AiCella, stated: 'Their deep expertise in automation and instrument development creates a powerful foundation for advancing smarter, more scalable cell therapy manufacturing.'

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large-scale global CDMO offering development, manufacturing, and fill-finish services across biologics, cell therapy, and consumer health. Most relevant comparable for Invetech's contract manufacturing and CGT automation positioning, though materially larger and broader in scope.

TypeBroad incumbent
Description

World's largest CDMO with deep biologics, cell & gene therapy, and small-molecule manufacturing capabilities. Direct comparable on the CGT automation and bioprocess tooling side, particularly for Korus/Alta-style platforms.

TypeBroad incumbent
Description

Leading bioprocessing supplier of upstream/downstream equipment, single-use consumables, and process automation. Comparable on the cell therapy bioprocess equipment, single-use consumables, and automation platform dimensions of Invetech's offering.

TypeBroad incumbent
Description

Operates one of the largest CDMO networks (Patheon) plus extensive life-sciences instrumentation and CGT services through brands such as Cell Therapy Systems. Comparable across Invetech's CDMO and diagnostic instrumentation footprint.

TypeDirect peer
Description

Cell & gene therapy focused manufacturer of automation platforms (CliniMACS Prodigy), single-use disposables, and reagents for cell processing. Closest direct peer to Invetech on integrated CGT automation with consumables and instrument-software coupling.

TypeDirect peer
Description

Privately held manufacturer of automated liquid handling workstations, lab automation, and process analytical instruments used in diagnostics and CGT workflows. Direct comparable on the precision-engineered, project-based IVD and life-sciences automation business.

TypeDirect peer
Description

Swiss manufacturer of laboratory automation, liquid handling, and IVD OEM components with strong project-based design and manufacturing services for diagnostic OEMs. Overlaps directly with Invetech's Ensemble modular diagnostic platform and IVD contract manufacturing offering.

TypeDirect peer
Description

Provider of laboratory automation, particle characterization, and bioprocess solutions for diagnostics, life-science research, and cell therapy. Comparable to Invetech's automation platform and consumables business serving diagnostics and CGT developers.

TypeDirect peer
Description

Specialist in containment, delivery, and processing components for injectable drugs and advanced therapies, with growing CGT and fill-finish capabilities. Comparable to Invetech's Alta fill-finish system and consumables business for cell therapies.

TypeEmerging player
Description

Supplies bioprocessing equipment, single-use consumables, and cell therapy workflow solutions. Comparable to Korus/Alta/Paddle Mixer on CGT bioprocessing hardware, though Cytiva is rooted in larger commercial-scale biopharma rather than diagnostics OEMs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Invetech

Medical Device Contract Manufacturinginvetechgroup.com

Invetech firmographics

Firmographics
Name
Invetech
Legal name
Invetech Pty. Ltd. and Invetech US LLC
Website
https://invetechgroup.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Invetech industry classification

Industry
Product category
Medical Device Contract Manufacturing
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Industrial Design Services (54142), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAGABAL
Process Development & Tech Transfer Services (CDMO)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Medical device manufacturing
  • Cell therapy automation
  • Diagnostic instrument development
  • Contract manufacturing services
  • IVD product engineering

Where Invetech is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Invetech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Manufacturing Services: Manufacturing services for clinical diagnostics instruments, life science instruments, and cell & gene therapy automation platforms. Revenue generated through NPI (New Product Introduction) manufacturing, pilot builds, and commercial-scale production. Operates through ISO 9001, ISO 13485, FDA-registered, ISO Class 7, and GMP manufacturing capabilities.
  2. Product Development Services: Design and engineering services from concept through regulatory-ready production. Includes full-service partnership, strategic engineering support, and sustaining engineering services. Revenue generated through project-based engagements.
  3. Proprietary Platforms and Modules: Sale of proprietary configurable automation platforms including Korus counterflow centrifuge, Alta formulation and filling systems, Paddle Mixers, and Ensemble modular platforms for diagnostics and CGT applications.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise contract manufacturing - project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Invetech product offering

Product offering

Core offering

Invetech designs, develops and manufactures proprietary automation platforms and provides full-service product development and contract manufacturing for in-vitro diagnostics (IVD) and cell & gene therapy (CGT) companies. The offering spans feasibility, design, engineering, regulatory-ready production and commercial-scale manufacturing, delivered alongside a portfolio of configurable products including the Korus counterflow centrifuge, Alta bag filling system, Paddle Mixer and Ensemble diagnostic platform.

Product overview

Invetech offers a platform-plus-modules architecture combining proprietary configurable automation products with comprehensive development and manufacturing services. The core product portfolio includes the Ensemble modular IVD development platform, Korus counterflow centrifuge system, Paddle Mixer for gentle cell mixing, Alta formulation and fill system, and Single-Use Consumables. These are complemented by service offerings in cell and gene therapy automation, IVD contract manufacturing, and product development services. The company operates manufacturing facilities in San Diego and Melbourne with ISO 13485, ISO 9001 certifications and FDA registration.

Differentiator

Problem solved

Functional benefit

Brands

  • Korus™: Counterflow Centrifugation System for cell washing and elutriation in cell therapy manufacturing.
  • Ensemble™
  • Alta™
  • Invetech Business Excellence (IBX)

Products and services

  • Invetech Ensemble Modular diagnostic platform that accelerates product development by combining proven core technologies with customizable configurations for translating assays from lab to benchtop IVD and point-of-care instruments.
  • Korus Counterflow Centrifuge System Automated counterflow centrifugation system for cell washing and elutriation in a closed, single-use system, producing cleaner starting material for downstream CGT processing with configurable protocols for different cell types and therapy workflows.
  • Paddle Mixer Configurable, low-shear GMP-compatible paddle mixer for cell and gene therapy bioprocessing, designed for gentle mixing of living cells to preserve cell viability with consistent, repeatable agitation across single-use bags.
  • Alta Formulation and Fill System Closed, automated bag filling system for aseptic fill and finish of advanced therapies that accurately dispenses therapeutic product into individual aliquot bags, replacing manual, variable, open processes with a GMP-ready fill operation.
  • Single-Use Consumables Purpose-built bags, tubing, fluid path assemblies, and custom components engineered for CGT manufacturing, co-designed with Invetech's automation equipment to deliver closed, aseptic workflows.
  • IVD Contract Manufacturing ISO-certified contract manufacturing services for clinical diagnostic and life science instruments, from pilot builds to commercial scale, including NPI manufacturing, design-to-manufacture transfer and ongoing production support.
  • Cell & Gene Therapy Automation Solutions Custom automation, configurable platforms, and proprietary systems for autologous and allogeneic cell and gene therapies, including end-to-end automation, single-use consumables development, and GMP-aligned manufacturing solutions.
  • Product Development Services Design and engineering services for diagnostics, medical devices and life sciences covering the full development journey from feasibility through regulatory-ready production, including feasibility, full-service partnership, strategic engineering support and sustaining engineering.

Quantifiable outcome

  • Defect rate reduction from 50% to <1% for point-of-care device manufacturing over 5 years
  • +3 more outcomes

Companies that use Invetech

Customer profile

Named customers12 records

Segments4 records

Ideal customer profiles3 records

Invetech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Invetech partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • General FluidicscoreStrategic or Co-development Partner · 4 June 2026Strategic collaboration announced June 4, 2026, with Invetech serving as General Fluidics' development and scaleup partner for its Axess point-of-care diagnostic platform. Invetech was selected after a global search spanning four continents for its end-to-end manufacturing capability and diagnostics expertise. The partnership aims to accelerate bringing high-quality diagnostic testing from central labs directly to clinics, urgent care centers, and rural settings.
  • Trenchant BioSystemscoreStrategic or Co-development Partner · 18 March 2026Strategic alliance to advance development and commercialization of Trenchant's fully automated AutoCell Platform for cell and gene therapy manufacturing. Testing data shows the platform could reduce CGT manufacturing costs by up to 80% and manufacturing time by up to 95%. The technology enables point-of-care production from a single unit of whole blood. Early access platform launch planned for early 2027, with full commercial release later that year.
  • AiCellacoreStrategic or Co-development Partner · 26 June 2025Strategic collaboration to advance cell therapy innovation. Geoffrey Stephens, CEO of AiCella, stated: 'Their deep expertise in automation and instrument development creates a powerful foundation for advancing smarter, more scalable cell therapy manufacturing.'

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Invetech competitors and assessment

Company assessment

Broad incumbents

  • Catalent: Large-scale global CDMO offering development, manufacturing, and fill-finish services across biologics, cell therapy, and consumer health. Most relevant comparable for Invetech's contract manufacturing and CGT automation positioning, though materially larger and broader in scope.
  • Lonza Group: World's largest CDMO with deep biologics, cell & gene therapy, and small-molecule manufacturing capabilities. Direct comparable on the CGT automation and bioprocess tooling side, particularly for Korus/Alta-style platforms.
  • Sartorius AG: Leading bioprocessing supplier of upstream/downstream equipment, single-use consumables, and process automation. Comparable on the cell therapy bioprocess equipment, single-use consumables, and automation platform dimensions of Invetech's offering.
  • Thermo Fisher Scientific (Patheon CDMO): Operates one of the largest CDMO networks (Patheon) plus extensive life-sciences instrumentation and CGT services through brands such as Cell Therapy Systems. Comparable across Invetech's CDMO and diagnostic instrumentation footprint.

Direct peers

  • Miltenyi Biotec: Cell & gene therapy focused manufacturer of automation platforms (CliniMACS Prodigy), single-use disposables, and reagents for cell processing. Closest direct peer to Invetech on integrated CGT automation with consumables and instrument-software coupling.
  • Hamilton Company: Privately held manufacturer of automated liquid handling workstations, lab automation, and process analytical instruments used in diagnostics and CGT workflows. Direct comparable on the precision-engineered, project-based IVD and life-sciences automation business.
  • Tecan: Swiss manufacturer of laboratory automation, liquid handling, and IVD OEM components with strong project-based design and manufacturing services for diagnostic OEMs. Overlaps directly with Invetech's Ensemble modular diagnostic platform and IVD contract manufacturing offering.
  • Beckman Coulter Life Sciences: Provider of laboratory automation, particle characterization, and bioprocess solutions for diagnostics, life-science research, and cell therapy. Comparable to Invetech's automation platform and consumables business serving diagnostics and CGT developers.
  • West Pharmaceutical Services: Specialist in containment, delivery, and processing components for injectable drugs and advanced therapies, with growing CGT and fill-finish capabilities. Comparable to Invetech's Alta fill-finish system and consumables business for cell therapies.

Emerging players

  • Cytiva (Danaher): Supplies bioprocessing equipment, single-use consumables, and cell therapy workflow solutions. Comparable to Korus/Alta/Paddle Mixer on CGT bioprocessing hardware, though Cytiva is rooted in larger commercial-scale biopharma rather than diagnostics OEMs.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Invetech social profiles

Digital presence

Invetech compliance and trust

Trust signal

Compliance3 records

Invetech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Invetech leadership team

Management profile

Number of profiles

Profiles8 records

Invetech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Invetech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invetech

What does Invetech do?

Invetech designs, develops and manufactures proprietary automation platforms and provides full-service product development and contract manufacturing for in-vitro diagnostics (IVD) and cell & gene therapy (CGT) companies. The offering spans feasibility, design, engineering, regulatory-ready production and commercial-scale manufacturing, delivered alongside a portfolio of configurable products including the Korus counterflow centrifuge, Alta bag filling system, Paddle Mixer and Ensemble diagnostic platform.

Is Invetech a public or private company?

Invetech is a private company. It is classified as management employee owned and is currently operating.

When was Invetech founded?

Invetech was founded in 1987. It employs 251 to 500 people.

Where is Invetech based?

Invetech is headquartered in San Diego, United States, in the North America region.

How does Invetech make money?

Three revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are product Development Services and proprietary Platforms and Modules.

Who are Invetech's main competitors?

Broad incumbents on record are Catalent, Lonza Group, Sartorius AG and Thermo Fisher Scientific (Patheon CDMO). Direct peers are Miltenyi Biotec, Hamilton Company, Tecan, Beckman Coulter Life Sciences and West Pharmaceutical Services. Cytiva (Danaher) is listed as an emerging player.

Does Invetech have an API?

No public API is recorded for Invetech.

What industry is Invetech in?

Invetech's product category is Medical Device Contract Manufacturing. Its primary akta.pro industry code is HLAGABAL, Process Development & Tech Transfer Services (CDMO), with a secondary code of HLAGAGAG, Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TrendHunter.comRapid Infection Diagnostic PlatformsMeMed and Invetech developed a compact rapid infection diagnostic platform that automates immunoassay testing to distinguish bacterial from viral infections in 15 minutes. The system supports MeMed's FDA-cleared BV test and earned a 2026 Gold Good Design Award for Engineering Design.PR Newswire APACInvetech & MeMed win 2026 Good Design Award Gold for MeMed Key™Invetech and MeMed won a 2026 Gold Good Design Award in the Engineering Design category for the MeMed Key, a compact immunoassay platform. The award recognizes the platform's design, innovation, and impact in translating a laboratory assay into a point-of-care diagnostic device.Laotian TimesInvetech & MeMed win 2026 Good Design Award Gold for MeMed Key™Invetech and MeMed won a 2026 Gold Good Design Award in Engineering Design for the MeMed Key, a compact immunoassay platform. The platform distinguishes bacterial from viral infections rapidly to support timely treatment decisions. The award recognizes the collaboration's engineering and human-centered design.PR Newswire APACInvetech & MeMed win 2026 Good Design Award Gold for MeMed Key™Invetech and MeMed won a 2026 Gold Good Design Award in the Engineering Design category for the MeMed Key, a compact immunoassay platform. The award recognizes the platform's design, innovation, and impact in translating a laboratory assay into a point-of-care diagnostic device.PR NewswireInvetech & MeMed win 2026 Good Design Award Gold for MeMed Key™Invetech and MeMed won a 2026 Gold Good Design Award in the Engineering Design category for the MeMed Key, a compact immunoassay platform. The platform distinguishes bacterial from viral infections rapidly to support timely treatment decisions. The award recognizes the collaboration's engineering and human-centered design.BriefglanceThe Quiet Revolution: How a New Partnership Aims to Reinvent Your VisitDiagnostic innovator General Fluidics and development firm Invetech have announced a strategic partnership to accelerate deployment of the Axess platform, a compact benchtop system capable of delivering blood diagnostic results in minutes rather than days, targeting the decentralization of routine lab testing. The collaboration arrives as the global point-of-care diagnostics market is projected to more than double from $43 billion in 2024 to nearly $88 billion by 2032. General Fluidics has raised $34.6 million to date, including a $22.6 million Series B round in mid-2024, while Invetech brings three decades of experience developing FDA and CE-approved medical devices to guide the platform through regulatory approval and scale manufacturing.PR NewswireGeneral Fluidics and Invetech Partner to Accelerate Accessible Diagnostics at the Point of CareGeneral Fluidics and Invetech announced a strategic collaboration on June 4, 2026, with Invetech serving as General Fluidics' development and scaleup partner for its Axess point-of-care diagnostic platform. After a global search spanning four continents, GF selected Invetech for its end-to-end manufacturing capability and diagnostics expertise. The partnership aims to accelerate bringing high-quality diagnostic testing from central labs directly to clinics, urgent care centers, and rural settings, with results available within minutes at point of care.Technology NetworksAlliance Advances Automated Cell Therapy ManufacturingTrenchant BioSystems Inc. announced a strategic alliance with Invetech to advance development and commercialization of Trenchant's fully automated AutoCell Platform for cell and gene therapy manufacturing. Testing data shows the platform could reduce CGT manufacturing costs by up to 80% and manufacturing time by up to 95%, with the technology enabling point-of-care production from a single unit of whole blood. The companies plan an early access platform launch in early 2027, followed by full commercial release later that year.GenengnewsFully-Automated CGT Manufacturing Platform Jointly Being Targeted by Trenchant BioSystems and InvetechTrenchant BioSystems and Invetech have agreed to collaborate on developing Trenchant's fully automated AutoCell Platform for cell and gene therapy (CGT) manufacturing, with plans for early access launch in early 2027 and full commercial release later that year. Testing data demonstrates the platform's potential to reduce manufacturing costs and time by eliminating certain ex vivo expansion steps, while sourcing T-cells from a single unit of whole blood drawn from the patient. Invetech will provide engineering, development, and manufacturing support leveraging its over 20-year track record in cell and gene therapy.